IL2 and graft versus host disease: In 10 pediatric patients, complete remissions (CRs) were achieved by KIR ligand-mismatched CD3-depleted and CD56-enriched NK cells (median dose, 26 × 106/kg) and six doses of IL-2 (1 million U/m2) without graft versus host disease (GVHD) and remained in CR for 2 years [37].